Latest News and Press Releases
Want to stay updated on the latest news?
-
TORONTO and HAIFA, Israel, July 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical results...
-
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
-
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...
-
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
-
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
-
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
-
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
-
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.